Weight in crease with the use of an tipsychot ics, es pe cially novel an tipsy chot ics, has been of sig nifi cant con cern to patients suf fer ing from psy chotic dis orders. There are sev eral psy cho so cial is sues as so ci ated with weight gain (for ex am ple, is sues of self-esteem, discrimi na tion, and medi cal mor bid ity). Stud ies and clini cal prac tice in volv ing an tipsy chotic use con sis tently in di cate weight gain as a po ten tially se ri ous side ef fect.
Weight in crease with the use of an tipsychot ics, es pe cially novel an tipsy chot ics, has been of sig nifi cant con cern to patients suf fer ing from psy chotic dis orders. There are sev eral psy cho so cial is sues as so ci ated with weight gain (for ex am ple, is sues of self-esteem, discrimi na tion, and medi cal mor bid ity). Stud ies and clini cal prac tice in volv ing an tipsy chotic use con sis tently in di cate weight gain as a po ten tially se ri ous side ef fect.
It has been stated that weight gain and loss may not be dosage-related. In my clini cal ob ser va tion on 2 dif fer ent oc casions, how ever, dos age ap peared to be re lated to weight loss af ter ini tial weight gain. I pres ent here the cases of 2 patients who lost weight, fol low ing ini tial gain.
Case Report 1
A 25-year-old man suf fer ing from schizo phre nia was pre scribed ol an zapine 20 mg daily (mono ther apy). His weight was re corded at 100 kg. He was clini cally sta ble. The dos age was reduced to 17.5 mg daily, and then to 15 mg daily, with no re bound in crease in psy cho sis. His re corded weight showed a re duc tion of 7 kg, ac com pa nied by more self-confidence in the pa tient. There was no other change in his medica tion regi men, diet, medi cal con di tion, lab val ues, or daily rou tine.
Case Report 2
A 37-year-old lady suf fer ing from schizoaf fec tive dis or der with manic and psychotic symp toms had a trial of sev eral mood sta bi liz ers, typi cal an tipsy chot ics, long-acting an tipsy chot ics, and clo zapine, with mul ti ple sub syn dro mal to full-blown symp toms and fre quent hospi tali sa tions. She was treated with 75 mg of topi ra mate and was started on olanzap ine with dose ti tra tion and fi nal increase to 20 mg daily. She ex pe ri enced a weight gain of 11 kg in 3 months. This com bi na tion of mood sta bi liz ers and olan zap ine led to sig nifi cant im prove ment in her men tal state. Ini tially, it was a daily strug gle keep ing her on ol an zapine, be cause she was ex tremely weightconscious. With im prove ment in her clini cal con di tion, ol an zap ine dos age was de creased to 17.5 mg daily, and then to 15 mg daily, with weight re duc tion of 3 kg. She was much more ac cept ing of ol an zap ine and was dis charged.
Based on these ob ser va tions, it is not pos si ble to de ter mine the mecha nism of ac tion lead ing to weight loss. Ol an zapine dos age re duc tion-wher ever pos sible at the ear li est op por tu nity-may, how ever, be a use ful strat egy to re duce weight fol low ing ini tial gain. 
Misleading Drug Advertising

Dear Edi tor:
It must be evi dent to all psy chia trists of my vin tage (over age 65 years) that pharma ceu ti cal com pany ad ver tis ing has changed re marka bly in the last 40 years. In the 1960s, bat tling the he gem ony of psy cho dy nami cally ori ented psy chia try, the drug com pa nies tim idly pro moted their prod ucts (some times, even the neuro lep tics) as ad juncts to psy cho ther apy (1). Now, we seem to be in an era wherein the aim of drug ad ver tis ing is to de value a com peti tor's prod uct in the hope of cast ing a fa vour able light on your own. For ex am ple, we have the al tru is tic folks at the Lilly Com pany in form ing us in a 2-page ad ver tise ment (2) of the dan gers of pro long ing the QTc in ter val, pos si bly in an tici pa tion of zi pra si done's in troduc tion by a com peti tor. We also have the thought ful peo ple at Jans sen tell ing us about the high in ci dence and dan gers of type 2 dia be tes, an in creased risk for those treated with ol an zap ine (3).
There is noth ing wrong with re ceiv ing fac tual in for ma tion. Every cli ni cian knows that the use of any drug for a particu lar pa tient re quires the ex er cise of sound judge ment and a care ful bal ancing of ad van tages against dis ad van tages. When drug com pa nies try to de ceive us, how ever, they lose credi bil ity; un for tunately, their spokes per sons may also lose credi bil ity. The fol low ing 2 ex amples are il lus tra tive.
The March 2001 is sue of Phy si cian Perspec tive, a news let ter sent through the mail by Eli Lilly Can ada Inc, con tained the "view point" of Ca na dian phy si cian, Joel Raskin, en ti tled "The New Atypicals and Ab nor mali ties in Glu cose Metabo lism: Real or Ex ag ger ated Risk?" Dr Raskin, who just hap pens to be the vice-president of clini cal re search for Lilly, states: "Risperi done and zi pra sidone were de signed to be have like haloperi dol, but with out giv ing rise to ex tra py ra mi dal symp toms." Any one aware of the pat tern of re cep tor block ade of these 2 drugs, and that of ha loperi dol (and oth ers, for ex am ple see [4] and [5]), will find this state ment grossly mis leading. A re cent ar ti cle by Ka pur and Seeman (6) is also rele vant.
A sec ond ex am ple: A friend of mine recently picked up a pam phlet in her family doc tor's of fice. Anxi ety-It's Not Just In Your Head was authored by Michael Evans, MD, and Rich ard Swin son, MD. Its pub li ca tion was "sup ported by an edu ca tional grant from Wyeth-Ayerst Can ada Inc," the mak ers of Ef fexor (ven la fax ine). The pam phlet is structured as a se ries of ques tions the prospec tive pa tient may have. Ques tion 13 reads as fol lows: "Are the medi ca tions ad dic tive? An ti de pres sants are not addic tive in the same way that ciga rettes or ben zo di azepines are." To sug gest that the ad dic tive po ten tial of ben zo diazepines is com pa ra ble with that of
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